BGE-102 for Diabetic Macular Edema

(QUELL-DME Trial)

This trial tests a new treatment called BGE-102 for individuals with diabetic macular edema (DME), a condition where diabetes causes swelling in the back of the eye, affecting vision. Researchers aim to determine if BGE-102 can improve vision or prevent further vision loss when used alone or with another drug. Participants will receive either BGE-102 with another eye treatment, BGE-102 alone, or a placebo with the other eye treatment to compare results. The trial is open to individuals with diabetes who have DME affecting their central vision and meet certain health requirements. As a Phase 2 trial, this research focuses on measuring how well BGE-102 works in an initial, smaller group of participants.

Studies have shown that BGE-102 is generally safe. In earlier trials, participants tolerated BGE-102 well, experiencing significant reductions in inflammation without major side effects. This suggests that BGE-102 could be safe for people with diabetic macular edema.

However, information on the long-term safety of BGE-102 remains limited. Researchers continue to collect data on its effects over time. So far, short-term use looks promising.

When combined with an anti-VEGF drug, BGE-102 may also be safe. Anti-VEGF treatments are commonly used for eye conditions like diabetic macular edema and help prevent vision loss by reducing unwanted blood vessel growth in the eye.

Researchers are excited about BGE-102 for diabetic macular edema because it offers a novel approach by being taken as an oral capsule, unlike the standard intravitreal injections like anti-VEGF therapies. BGE-102 works differently by potentially offering a more convenient and less invasive option for patients. Additionally, when combined with anti-VEGF therapy, it could enhance the overall effectiveness, possibly leading to better vision outcomes compared to current treatments alone.

Research has shown that BGE-102, which participants in this trial may receive, might help treat diabetic macular edema (DME) by reducing inflammation, potentially improving vision or slowing vision loss. Patients who have received similar treatments experienced significant improvements in their vision. In this trial, some participants will receive a combination of BGE-102 with anti-VEGF, a treatment that stops harmful blood vessel growth and has also shown promise. Studies have found that anti-VEGF treatments alone can significantly improve vision, with patients seeing an average improvement of 8.6 letters on an eye chart over two years. Using these therapies together may lead to better results by addressing different aspects of the condition.⁶⁷⁸⁹¹⁰